Introduction
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Biosimilars which derives maximum revenue, Generics, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene. Geographically, the company generates a majority of its revenue from its customers located in India and the rest from Brazil, Singapore, and the rest of the world.
Information is being updated
You need to login to view information
Charter capital
Business Size and Operations
Company Size
Total Assets
| A10 (Bellow 100 B) | A9 (100 - 200 B) | A8 (200 - 400 B) | A7 (400 - 600 B) | A6 (600 - 800 B) |
| A5 (800 - 1000 B) | A4 (1000 - 1500 B) | A3 (1500 - 2000 B) | A2 (2000 - 2500 B) | A1 (Above 2500 B) |
Owner’s Equity
| E10 (Bellow 100 B) | E9 (100 - 200 B) | E8 (200 - 400 B) | E7 (400 - 600 B) | E6 (600 - 800 B) |
| E5 (800 - 1000 B) | E4 (1000 - 1500 B) | E3 (1500 - 2000 B) | E2 (2000 - 2500 B) | E1 (Above 2500 B) |
Business Activities
Revenue
| R10 (Bellow 100 B) | R9 (100 - 200 B) | R8 (200 - 400 B) | R7 (400 - 600 B) | R6 (600 - 800 B) |
| R5 (800 - 1000 B) | R4 (1000 - 1500 B) | R3 (1500 - 2000 B) | R2 (2000 - 2500 B) | R1 (Above 2500 B) |
Number of employee
| L10 (Bellow 100 Peoples) | L9 (100 - 200 Peoples) | L8 (200 - 400 Peoples) | L7 (400 - 600 Peoples) | L6 (600 - 800 Peoples) |
| L5 (800 - 1000 Peoples) | L4 (1000 - 1500 Peoples) | L3 (1500 - 2000 Peoples) | L2 (2000 - 2500 Peoples) | L1 (Above 2500 Peoples) |
Company’s Market Position
Profitability within the Industry
Return on Total Assets (ROA)
| Bottom 25% | 25%-m | m-25% | Top 25% |
Return on Equity (ROE)
Net Profit Margin (ROS)
Current Ratio
| Bottom 25% | 25%-m | m-25% | Top 25% |
Total asset turnover
| Bosttom 25% | 25%-m | m-25% | Top 25% |